Some have relabeled it as Pentadecapeptide Aringate or PDA (changing the acetate to an arginate) and so are prescribing it for subcutaneous administration this way, when the confusion about its status has triggered a vivid oral capsule market for BPC in what appears to get a gray space of legality. https://agnesi776izr6.slypage.com/profile